Boundless Bio, Inc.

Boundless Bio, Inc. is a clinical-stage oncology company dedicated to developing novel cancer therapeutics. Headquartered in San Diego, CA, the company's mission is to be the foremost biopharmaceutical entity interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies for patients with oncogene-amplified cancers.

The company focuses on targeting ecDNA, identified as a root cause of oncogene amplification in over 17% of cancer patients. Boundless Bio utilizes its proprietary Spyglass platform to identify essential targets for ecDNA functionality in cancer cells, subsequently designing and developing small-molecule drugs known as ecDNA-directed therapies (ecDTx). Its lead therapeutic candidate, BBI-940, is an oral kinesin degrader currently in a Phase 1/2 clinical trial for specific breast cancer subtypes. The company previously advanced BBI-355, an oral CHK1 inhibitor, and BBI-825, an oral RNR inhibitor, through clinical trials, but has since strategically prioritized BBI-940. Additionally, Boundless Bio is developing ECHO (ecDNA Harboring Oncogenes), a proprietary diagnostic algorithm to detect ecDNA from next-generation sequencing data, aiding in patient selection.

Led by CEO, President, and Director Zachary Hornby, Boundless Bio went public on March 28, 2024. Recent developments include the FDA's acceptance of the Investigational New Drug (IND) application for BBI-940 in January 2026, leading to the initiation of the KOMODO-1 first-in-human trial. Preclinical data for BBI-940 in breast cancer was presented at the 2026 AACR Annual Meeting. The company reported its fourth quarter and full-year 2025 financial results in March 2026, projecting a cash runway into the second half of 2028.